Fereshteh Alsahebfosoul

Prof. Fereshteh Alsahebfosoul

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 February 2020 in Immunological Investigations
Verified
Journal Article
Closed access
MJMorteza Jafarinia
Morteza Jafarinia
FAFereshteh Alsahebfosoul
Fereshteh Alsahebfosoul
HSHossein Salehi
Hossein Salehi
NEnahid eskandari
nahid eskandari
MGMazdak Ganjalikhani-Hakemi
Mazdak Ganjalikhani-Hakemi
In recent years, mesenchymal stem/stromal cells (MSCs) have widely been considered as therapeutic tools in basic researches and clinical trials. Accumulating evidence supports the idea that MSCs perform their therapeutic roles in paracrine manner especially through trophic factors and extracellular vesicles (EVs). Compared to cells, EVs have several advantages to be used as therapeutic agents, such as they lack self-replicating capabilities, dangers of ectopic differentiation, and tumor formation, genetic instability, and cellular rejection by the immune system. Since the MSC-derived EVs (MSC-EVs) appear to exert similar therapeutic effects of their parent cells, such as ability to arrive themselves to the site of injury and immunomodulatory properties, MSC-EVs have been widely studied in many animal models, including kidney, liver, cardiovascular, immunological, and neurological diseases. Regarding this, MSC-EVs look to be a novel and interesting approach to be studied in clinical trials of different inflammatory diseases. In this review, we summarize the properties and applications of MSC-EVs in different diseases.

1 August 2014 in Immunological Investigations
Verified
Journal Article
Closed access
FAFereshteh Alsahebfosoul
Fereshteh Alsahebfosoul
MEMasoud Etemadifar
Masoud Etemadifar
NSNahid Sedaghat
Nahid Sedaghat
MSMansoureh Shahbazi
Mansoureh Shahbazi
FFFatemeh Pourgadegan Firouzabadi
Fatemeh Pourgadegan Firouzabadi
HDHoda Mohammad Dezashibi
Hoda Mohammad Dezashibi
Multiple sclerosis (MS) is a chronic neuroinflammatory disease with unknown etiology and variable clinical evolution. Interleukin-23 (IL-23), a member of the IL-12 cytokine family is a heterodimeric cytokine composed of the IL-12p40 subunit, and with a novel p19 subunit, its ability to enhance the expansion of T helper type 17 (Th17) cells indicates the responsibility for many of the inflammatory autoimmune responses. The objective of the project is to measure IL-23 level in plasma of multiple sclerosis (MS) patients in comparison with healthy control subjects. In a case-control study, plasma was collected from healthy subjects as control group (n = 40) and patients with relapsing remitting multiple sclerosis (RRMS) (n = 40). The plasma level of IL-23 was assessed by ELISA method. Statistical analysis was performed with SPSS (Ver. 16). Plasma level of IL-23 in MS patients was significantly increased compared to control subjects (p Value < 0.001). Our findings revealed the increased IL-23 level in patients' group. In conclusion, the inhibition of IL-23 might be a novel and promising therapeutic strategy, especially in the therapy of autoimmune inflammatory diseases. IL-23 plays a pivotal role in development of MS and might be a specific marker and therapeutic target for MS.

1 April 2017 in Gene
Verified
Journal Article
Closed access
MRMahsa Rezaeepoor
Mahsa Rezaeepoor
SSShima Shapoori
Shima Shapoori
MGMazdak Ganjalikhani-Hakemi
Mazdak Ganjalikhani-Hakemi
MEMasoud Etemadifar
Masoud Etemadifar
FAFereshteh Alsahebfosoul
Fereshteh Alsahebfosoul
MMMarjan Mansourian
Marjan Mansourian

20 January 2017 in BioMolecular Concepts
Verified
Journal Article
Open access
PDF file
FAFereshteh Alsahebfosoul
Fereshteh Alsahebfosoul
IRIlnaz Rahimmanesh
Ilnaz Rahimmanesh
MSMansour Shajarian
Mansour Shajarian
MEMasoud Etemadifar
Masoud Etemadifar
NSNahid Sedaghat
Nahid Sedaghat
SNShamsi Naderi
Shamsi Naderi
Cytokines are implicated in the immunopathogenesis of multiple sclerosis (MS). Interleukin (IL)-33, one of the recently discovered members of the IL-1 superfamily, is a dual functional cytokine involved in various autoimmune disorders. In a case-control study, venous blood was collected from healthy subjects categorized as control group (n=44) and MS patients (n=44). All recruited patients were clinically diagnosed with relapsing-remitting MS (RRMS), including patients without treatment (new identified cases, n=16) and those treated with interferon beta (IFN-β) (n=28). The plasma levels of IL-33 in subjects were measured with ELISA. Significantly elevated IL-33 plasma levels were observed in RRMS patients ( p =0.005). Furthermore, IFN-β-treated MS patients had lower levels of IL-33 compared to the untreated patients ( p <0.001). Increased IL-33 plasma levels in the patient group might be associated with development of MS. These results could contribute to our better understanding about the role of IL-33 in the immunopathogenesis of MS.

22 January 2020 in BMC Research Notes
Verified
Journal Article
Open access
PDF file
RARazieh Alipour
Razieh Alipour
AFAlimohammad Fatemi
Alimohammad Fatemi
FAFereshteh Alsahebfosoul
Fereshteh Alsahebfosoul
AAAlireza Andalib
Alireza Andalib
APAbbasali Pourazar
Abbasali Pourazar
Objective: Currently, the replacement of fetal calf serum (FCS) by a more suitable alternative is a sought aim in the field of tissue and cell culture research. Autologous plasma (AP) and especially autologous serum (AS) have been shown to be effective substitutes of FCS in culture media for some of the cell types. Nevertheless, there is no comparative data on the most appropriate supplement for cell media in neutrophil studies, it is now unclear whether AP have a relatively equal, superior or inferior performance to FCS in neutrophil cell culture. In the present study, human blood neutrophils were isolated and cultured in FCS- or AP-supplemented medium. After 12, 36 and 60 h of incubation, cell viability, oxidative burst and CD11b expression were determined by flow cytometry.Results: Compared to the culture of neutrophils in FCS 10% medium, the culture of neutrophils in a medium with AP 10% could prolong their life span without affecting their function. The findings introduce AP as a better supplement for human neutrophil cell culture than FCS and propose a simple and economical procedure for neutrophil isolation and culture.

3 December 2019 in International Journal of Neuroscience
Verified
Journal Article
Closed access
MJMorteza Jafarinia
Morteza Jafarinia
ESErfan Sadeghi
Erfan Sadeghi
FAFereshteh Alsahebfosoul
Fereshteh Alsahebfosoul
MEMasoud Etemadifar
Masoud Etemadifar
HJHamidreza Jahanbani-Ardakani
Hamidreza Jahanbani-Ardakani
Background: Multiple sclerosis (MS) is known as a neuroinflammatory disease of the central nervous system (CNS). The neuroinflammation may induce pro-inflammatory cytokines such as Osteopontin (OPN). OPN plays an important role in the inflammation by modulating the T helper1 (Th1) and Th17 responses. Since the exact immune pathogenesis of MS is complex and not well defined and many factors are involved, the need to detect more contributing biomarkers may help in setting new therapeutic strategies. Objective: This study tried to compare plasma OPN levels in relapsing- remitting multiple sclerosis (RRMS) patients during the remission phase with healthy subjects in Isfahan province. Materials and methods: In a case-control study, plasma was collected from the 40 RRMS as well as 38 (age and sex matched) healthy individuals as a control group. PlasmaOPN level was measured and compared between the two groups by Enzyme-linked immunosorbent assays (ELISA). Result: Statistical analysis revealed that plasma OPN level was markedly higher in the case group (RRMS patients during the remission phase) compared with the control group (P- value = 0.039). Our results also showed that there was no statistically significant difference in mean of plasma OPN level among RRMS patients who were treated with interferon (IFN)-ß and those who were not (P- value = 0.332). There was also no correlation between OPN plasma level and EDSS score (r = 0.037, P- value = 0.835), age of onset (r = 0.161, P- value = 0.357) and duration of disease (r = 0.121, P- value = 0.490). Conclusion: Higher OPN plasma level in studied patients suggests that OPN increased in RRMS patients who were in remission phase. It could be hypothesized that plasma OPN level may be increased as part of the pro-inflammatory cytokine milieu taking place in MS patients. OPN may not be specific marker for MS, but targeting it might present promising therapeutic effect to MS patients.